KALA BIO announced that its CHASE Phase 2b clinical trial of KPI-012 for the treatment of persistent corneal epithelial defect did not meet the primary endpoint of complete healing of PCED as measured by corneal fluorescein staining. The CHASE trial also failed to achieve statistical significance for key secondary efficacy endpoints and did not show any meaningful difference between either KPI-012 treatment arm and the placebo arm.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA:
- Kala Pharmaceuticals Sets Date for Annual Meeting
- Strategic Positioning and Trial Design Propel Kala Pharmaceuticals to ‘Buy’ Rating
- Kala Pharmaceuticals price target raised to $35 from $12 at H.C. Wainwright
- Kala Pharmaceuticals price target raised to $33 from $15 at Oppenheimer
- Kala Pharmaceuticals initiated with an Outperform at Mizuho